Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.31 |
| ▸ | GABRP | O00591 | 3/20 | 0.31 |
| ▸ | GABRD | O14764 | 3/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420550 | 1.00 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL4419903 | 1.00 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL4423815 | 1.00 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL27915349 | 1.00 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL16753714 | 1.00 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL4426649 | 1.00 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL189157 | 1.00 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28009300 | 0.98 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15533962 | 0.98 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL7044455 | 0.81 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250130224-A1 | PHOTOREACTIVE ANTIBODY BINDING DOMAINS WITH EPITOPE TAGS FOR MULTIPLEXED ANTIBODY LABELING, DETECTION, AND PURIFICATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-04-24 | — | — | US | claimed |
| EP-4380620-A2 | PHOTOREACTIVE ANTIBODY BINDING DOMAINS WITH EPITOPE TAGS FOR MULTIPLEXED ANTIBODY LABELING, DETECTION, AND PURIFICATION | The Trustees of The University of Pennsylvania (US) | 2024-06-12 | — | — | EP | claimed |
| CN-116675951-A | Fluorine-containing epoxy resin for high-performance carbon fiber prepreg and preparation method thereof | 山东万亿体育健康服务有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-116365044-A | Electrolyte, secondary battery and electric equipment | 欣旺达电动汽车电池有限公司 | 2023-06-30 | — | — | CN | claimed |
| WO-2023014778-A2 | PHOTOREACTIVE ANTIBODY BINDING DOMAINS WITH EPITOPE TAGS FOR MULTIPLEXED ANTIBODY LABELING, DETECTION, AND PURIFICATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-02-09 | — | — | WO | claimed |
| US-20130012690-A1 | METHOD FOR STABILIZATION OF PROTEINS USING NON-NATURAL AMINO ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-01-10 | — | — | US | claimed |
| US-20090326196-A1 | Proteins Containing a Fluorinated Amino Acid, and Methods of Using Same | TRUSTEES OF TUFTS COLLEGE | 2009-12-31 | — | — | US | claimed |
| US-20090221790-A1 | METHOD FOR STABILIZATION OF PROTEINS USING NON-NATURAL AMINO ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2009-09-03 | — | — | US | claimed |
| EP-1993582-A2 | PROTEINS CONTAINING A FLUORINATED AMINO ACID, AND METHODS OF USING SAME | Trustees Of Tufts College (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2007084527-A2 | PROTEINS CONTAINING A FLUORINATED AMINO ACID, AND METHODS OF USING SAME | TRUSTEES OF TUFTS COLLEGE (US) | 2007-07-26 | — | — | WO | claimed |
| US-20040214988-A1 | Method for stabilization of proteins using non-natural amino acids | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2004-10-28 | — | — | US | claimed |
| JP-61254544-A | — | — | None | — | — | JP | disclosed |
| EP-4687443-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | Genepep (FR) | 2026-02-11 | — | — | EP | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2001027140-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | CYTOVIA, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1076563-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6153591-A | PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS | CYTOVIA, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999047154-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
| JP-S61254544-A | PRODUCTION OF 4,4,4-TRIFLUOROVALINE COMPOUND | ASAHI GLASS CO LTD | 1986-11-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | SLC7A5 1405/4885SLC1A3 1024/4885SLC1A2 1557/4885 |
| US-20090326196-A1 | Proteins Containing a Fluorinated Amino Acid, and Methods of Using Same | DNPEP, NPEPPS, ANPEP | SLC7A5 618/4885SLC1A3 385/4885SLC1A2 647/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | SLC7A5 1050/4885SLC1A3 595/4885SLC1A2 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.